A third Phase 1b/2a study of VNA-318

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 20 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Dec 2024 According to a Vandria media release, company has closed a $32M Series A to fund its Phase 1 trial, its analysis, and to plan for the efficacy-focused Phase 1b / 2a trials of VNA-318 with the first expected to commence in Q1 2026 or earlier.
22 Aug 2024 New trial record
21 Aug 2024 According to a Vandria media release, the company received $30.7M (CHF28.3M) series A financing proceeds will be used for completion of phase I trial and the initiation of three parallel Phase 1b / 2a efficacy studies planned for 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com